Related Experiment Video
Updated: May 23, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Use of Integrase Strand Transfer Inhibitors Among Children Living With HIV in Latin America and the Caribbean
Marco Tulio Luque1, Liping Du2, Vanessa Rouzier3
1From the Departamento de Pediatria, Hospital Escuela, Tegucigalpa, Honduras.
Insights
Integrase strand transfer inhibitor (INSTI) use, including dolutegravir (DTG) and raltegravir (RAL), has increased among children with HIV in Latin America and the Caribbean. Further research is needed to understand the clinical impact of these HIV treatments in pediatric populations.
Area of Science:
- Pediatric infectious diseases
- HIV/AIDS treatment
- Pharmacovigilance in children
Background:
- Limited data exist on integrase strand transfer inhibitor (INSTI) use in pediatric populations.
- Assessing dolutegravir (DTG) and raltegravir (RAL) use and outcomes in children with HIV in Latin America and the Caribbean is crucial.
Purpose of the Study:
- To evaluate trends and factors associated with INSTI initiation (DTG/RAL) in children with HIV.
- To compare viral and treatment outcomes based on INSTI use in pediatric HIV care.
Main Methods:
- Analysis of data from pediatric cohorts in Brazil, Haiti, and Honduras (2013-2022).
- Utilized multivariable logistic and Cox regression models for ART-naïve and ART-experienced children, respectively.
- Log-rank tests were used to compare outcomes between INSTI users and non-users in ART-naïve children.
Main Results:
- INSTI initiation, particularly DTG, increased significantly among ART-naïve children from 2016 to 2022.
- Older age and more recent calendar years were associated with higher DTG initiation rates in ART-naïve children.
- No significant difference in virologic suppression was observed between DTG users and non-users, but DTG users had longer first-regimen duration.
Conclusions:
- INSTI use has demonstrably increased among children with HIV in parts of Latin America and the Caribbean.
- The clinical impact of INSTI regimens in pediatric HIV management requires further investigation.
Background:
Limited data exist on integrase strand transfer inhibitor (INSTI) use among children. We assessed dolutegravir (DTG) and raltegravir (RAL) use and outcomes among Latin American and Caribbean children with HIV.
Methods:
Cohorts from Brazil, Haiti and Honduras contributed data for children (age <18 years) receiving care since the widespread availability of DTG and RAL (approximately 2013-2022). Trends and factors associated with INSTI (DTG/RAL) initiation were examined using multivariable logistic and Cox regression models among antiretroviral therapy (ART)-naïve and -experienced children, respectively. We compared viral and treatment outcomes among ART-naïve children by INSTI use with log-rank tests.
Results:
Among ART-naïve children, 77/110 started DTG, 5/109 started RAL and 91 started other ART. The proportion of ART-naïve children initiating DTG increased from 0% in 2016 to 93% (13/14) in 2022. Starting DTG was more likely in older ART-naïve children and in more recent calendar years (P ≤ 0.01). Among ART-experienced children, 122/273 switched to DTG, and 25/288 switched to RAL. More recent calendar year and a greater number of prior ART regimens were associated with a higher incidence of switch to DTG and RAL (P < 0.01). There was no statistical difference in virologic suppression among ART-naïve children by use or non-use of DTG; however, children started on DTG had a longer duration of the first regimen than those started on other ART (P < 0.01).
Conclusions:
INSTI use among children has increased in parts of Latin American And Caribbean. As more children start INSTI regimens, further research is needed on their clinical impact.
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Retroviruses
Subviral Agents
Inhibitors of Viral Protein Synthesis

